NSE: DRREDDYPharmaceuticals
Dr. Reddy's Laboratories Ltd
Industry: Generics & Biosimilars·Market Cap: ₹1.08 Lakh Cr
Halal
AAOIFI Standard Verdict
Is DRREDDY halal? Yes — According to AAOIFI standards, this stock is Shariah-compliant.
Market Valuation & Pricing
Market Price
₹6,545.00
As of 7 Nov 2026Market Capitalization
₹1.08 Lakh Cr
Used as denominator for Shariah debt & cash capsPrice-to-Earnings (P/E)
20.8x
Trailing 12-month valuation multiple52-Week Range51% of range
Low: ₹5,301.45High: ₹7,723.10
4-Quarter Shariah Compliance Trend
Illustrative trend · Based on quarterly NSE filings
Consistently Compliant (≤ 20%)
Debt Ratio Track30% AAOIFI Limit
Illustrative trend · Based on quarterly NSE filingsFinancial Ratios Breakdown (AAOIFI)
Analysis of 3 core Shariah financial ratios based on audited quarterly balance sheet filings:
DEBT
Interest-bearing Debt / Market Cap
Pass
1.81%actual
Allowed Limit≤ 30%
CASH
Cash & Interest Securities / Market Cap
Pass
6.02%actual
Allowed Limit≤ 30%
INCOME
Non-Halal Revenue / Total Revenue
Pass
0.00%actual
Allowed Limit≤ 5%
Tazkiyah (Dividend Purification)
0.00% Required0.00% purification required. According to audited filings, DRREDDY has zero reported impermissible non-core income.
Methodology Comparison
Compare standard AAOIFI vs. Tayyib Taqwa Screen:
| Standard | Verdict | Debt Ratio | Cash / Liquidity | Impure Income | Sector Check |
|---|---|---|---|---|---|
AAOIFI Standard Global Islamic Benchmark (≤30% / ≤5%) | Halal | 1.81% (≤30%) | 6.02% (≤30%) | 0.00% (≤5%) | Pharmaceuticals |
Taqwa Mode Strict Screen (≤20% / ≤1%) | Halal | 1.81% (≤20%) | 6.02% (≤20%) | 0.00% (≤1%) | Permissible |
Filing & Source Information
Primary SectorPharmaceuticals
Sub-IndustryGenerics & Biosimilars
Data Freshness7 Nov 2026
Primary SourceNSE / Yahoo Financials
Important Disclaimer: This screening is for informational purposes only and does not constitute a formal fatwa or investment recommendation. Always consult a qualified Shariah scholar and a certified financial advisor before making investment decisions. Read our full methodology →